MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-100111-PIP01-21

Scope of the Application

Active Substance(s)

DORAVIRINE; Islatravir

Condition(s)

Treatment of human immunodeficiency virus-1 (HIV-1) infection.

Pharmaceutical Form(s)

Tablet; Age appropriate solid dosage form

Route(s) of Administration

Oral use

Name / Corporate name of the PIP applicant

Merck Sharp and Dohme (UK) Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp and Dohme (UK) Limited submitted to the licensing authority on 24/05/2021 20:37 BST an application for a Paediatric Investigation Plan

The procedure started on 25/10/2021 15:38 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100111-PIP01-21

Of 03/11/2021 12:28 GMT

On the adopted decision for DORAVIRINE; Islatravir (MHRA-100111-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan (including a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Paediatric Investigation Plan for DORAVIRINE; Islatravir, Tablet; Age appropriate solid dosage form , Oral use .

This decision is addressed to Merck Sharp and Dohme (UK) Limited, 120 Moorgate, London, United Kingdom, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Treatment of human immunodeficiency virus-1 (HIV-1) infection. The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 28 days of age Pharmaceutical form(s): Tablet Route(s) of administration: Oral use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments;

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of human immunodeficiency virus-1 (HIV-1) infection.

2.2 Indication(s) targeted by the PIP:

Treatment of human immunodeficiency virus-1 (HIV-1) infection.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 28 days old to less than 18 years of age

2.4 Pharmaceutical Form(s):

Tablet; Age appropriate solid dosage form

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age appropriate oral solid dosage form
Non-Clinical Studies	0	Not applicable
Clinical Studies	2	Study 2 (P028) Open label uncontrolled study to evaluate islatravir (MK-8591) PK and the safety and efficacy of doravirine with islatravir (DOR -ISL) in paediatric participants with HIV-1 infection who are less than 18 years of age and weigh at least 35 kg Study 3 Open label uncontrolled pharmacokinetic (PK), safety and activity study of the fixed dose combination of DOR-ISL (age appropriate formulation) for paediatric subjects who are at least 28 days of age and weigh less than 35 kg
Extrapolation, Modeling & Simulation Studies	2	Study 4 Modelling and simulation study to support islatravir dose finding in paediatric participants less than 18 years of age and weighing at least 35kg Study 5 Modelling and simulation study to support islatravir dose finding in paediatric participants who are at least 28 days of age and weigh less than 35 kg
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes

Date of completion of the paediatric investigation plan:	31/03/2028
Deferral of one or more studies contained in the paediatric investigation plan:	Yes